Regeneron, Bayer Hit Back In Eye Med Biosimilar Clash
Regeneron and Bayer have pushed back against British pharmaceutical company Advanz, defending the validity of their U.K. eye medicine patents in an ongoing feud over the planned launch of a competing...To view the full article, register now.
Already a subscriber? Click here to view full article